Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emirodatamab, an antibody targeting FLT3 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dalutrafusp, an antibody targeting TGFBR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anumigilimab, an antibody targeting CSF3R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zeripatamig, an antibody targeting CD47 × CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ralzapastotug, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Prafnosbart, an antibody targeting ACVR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pradusinstobart, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Patecibart, an antibody targeting EDNRA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozekibart, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obertamig, an antibody targeting CD3E × HLA-G.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lipustobart, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Epacmarstobart, an antibody targeting SIRPA.